Redbiotec
Redbiotec is a privately held Swiss biotech founded in 2006 and headquartered in Schlieren, developing engineered therapeutic bacteria for cancer and genetic disorders. The firm operates with 11–50 employees under founder leadership and has no disclosed commercial revenue.
- Company typePrivate
- Founded2006
- HeadquartersSchlieren, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Redbiotec does
Redbiotec is a privately held Swiss biotechnology company founded in 2006 and headquartered in Schlieren, Switzerland. The company positions itself as a pioneer in therapeutic bacteria, developing biological treatments for cancer and genetic disorders. With 11–50 employees and a for-profit structure, Redbiotec operates as a small, founder-led research entity. The firm's core technology centers on engineered bacteria deployed as a therapeutic modality, though pipeline assets, mechanisms of action, and platform architecture are not disclosed in available sources.
The company was co-founded by Christian Schaub (CEO) and Corinne John (CTO), indicating an R&D-led organization with retained founder technical leadership. Redbiotec's web domain is registered at redbiotec.ch, but the source content is not accessible beyond a verification loader, and no product detail, pricing model, customer list, partnership, patent count, or certification is captured in the inputs. As a result, the disclosed surface area is limited to firmographics, leadership, and a single historical financing event.
The only documented capital event is a 2014 funding round with redalpine as lead investor (no amount captured). There is no evidence of commercialization, licensing revenue, product launches, regulatory milestones, partnerships, or M&A activity in the inputs. Given the absence of revenue, pricing, and customer data, Redbiotec appears to operate as a research-stage biotech without commercial sales at present, and any assessment of operating cadence or pipeline maturity would require additional disclosure or direct diligence.
Redbiotec firmographics
Firmographics- Name
- Redbiotec
- Website
- https://redbiotec.ch
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Redbiotec is a privately held Swiss biotech founded in 2006 and headquartered in Schlieren, developing engineered therapeutic bacteria for cancer and genetic disorders. The firm operates with 11–50 employees under founder leadership and has no disclosed commercial revenue.
- Ownership category
- akta.pro rank
Redbiotec industry classification
Industry- Product category
- Therapeutic Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
- akta.pro secondary industries
- Consortia & Defined Microbial Community Therapeutics (HLAAAFAC), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)
Keywords
Where Redbiotec is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Redbiotec business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Redbiotec product offering
Product offeringCore offering
Redbiotec is a biotechnology company pioneering the development of engineered therapeutic bacteria aimed at treating cancer and inherited genetic disorders. The company focuses on synthetic biology and microbial engineering to build a pipeline of bacterial-based biotherapeutic candidates for oncology and rare genetic disease indications.
Product overview
No product information available. The source content displays only a loading/verification page rather than substantive company information.
Differentiator
Problem solved
Functional benefit
Products and services
- Engineered therapeutic bacteria pipeline A pipeline of engineered therapeutic bacterial strains designed to treat cancer and inherited genetic disorders; intended for licensing or co-development with biopharmaceutical partners.
Companies that use Redbiotec
Customer profileIdeal customer profiles1 record
Redbiotec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Redbiotec partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Redbiotec competitors and assessment
Company assessmentDirect peers
- Synlogic: Clinical-stage biotech engineering Synthetic Biotics (engineered probiotic strains) to treat rare diseases, oncology, and metabolic disorders. Most directly comparable to Redbiotec in modality, approach, and therapeutic focus.
- Vedanta Biosciences: Develops defined bacterial consortia as oral therapies for immune-mediated diseases and cancer. Comparable to Redbiotec in using rationally designed microbial therapeutics for serious diseases.
- T3 Pharmaceuticals: Swiss-based biotech engineering live bacteria to deliver therapeutic proteins for cancer. Directly comparable as a geographically close peer working on engineered therapeutic bacteria in oncology.
- Eligo Bioscience: Pioneers of Eligobiotics — engineered phage-based and microbial platforms delivering therapeutics in situ. Comparable to Redbiotec in synthetic biology engineering of microbes for therapeutic effect.
- Actym Therapeutics: Develops engineered microbial immunotherapies that deliver DNA-based payloads to tumor microenvironments. Directly comparable in using engineered bacteria to treat cancer.
- Novome Biotechnologies: Engineers defined microbial consortia for genetic disorders (notably hyperoxaluria) and other indications. Comparable to Redbiotec in the genetic-disorder therapeutic area and engineered-microbe modality.
- Locus Biosciences: Develops engineered bacteriophage and bacterial products to treat bacterial infections and microbiome-related diseases. Overlaps with Redbiotec in synthetic biology approaches to microbial therapeutics.
Broad incumbents
- Seres Therapeutics: Late-stage microbiome therapeutics company with an approved Ecobiotic product (VOWST) and pipeline across infectious disease and oncology. Broader and more mature than Redbiotec but operating in the same engineered/consortium microbiome space.
- Novonesis (formerly Novozymes): Global industrial biotech and enzymes powerhouse with growing activity in microbiome and health-related microbial engineering. Broader and far larger than Redbiotec but relevant as a demonstration of where engineered-microbial platforms can scale commercially.
Emerging players
- Second Genome: Microbiome-focused biotech discovering and developing therapeutics based on microbial biology for oncology and inflammatory disease. Comparable to Redbiotec as a smaller microbiome therapeutics peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Redbiotec social profiles
Digital presenceRedbiotec financial estimates
Financial estimateRevenue estimate
Valuation estimate
Redbiotec leadership team
Management profileNumber of profiles
Profiles2 records
Redbiotec funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Redbiotec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Redbiotec
What does Redbiotec do?
Redbiotec is a biotechnology company pioneering the development of engineered therapeutic bacteria aimed at treating cancer and inherited genetic disorders. The company focuses on synthetic biology and microbial engineering to build a pipeline of bacterial-based biotherapeutic candidates for oncology and rare genetic disease indications.
Is Redbiotec a public or private company?
Redbiotec is a private company. It is classified as venture growth investor backed and is currently operating.
When was Redbiotec founded?
Redbiotec was founded in 2006. It employs 11 to 50 people.
Where is Redbiotec based?
Redbiotec is headquartered in Schlieren, Switzerland, in the Europe region.
Who are Redbiotec's main competitors?
Direct peers on record are Synlogic, Vedanta Biosciences, T3 Pharmaceuticals, Eligo Bioscience, Actym Therapeutics, Novome Biotechnologies and Locus Biosciences. Broad incumbents are Seres Therapeutics and Novonesis (formerly Novozymes). Second Genome is listed as an emerging player.
Does Redbiotec have an API?
No public API is recorded for Redbiotec.
What industry is Redbiotec in?
Redbiotec's product category is Therapeutic Biologics. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAFAC, Consortia & Defined Microbial Community Therapeutics. Its NAICS code is 325414 and its SIC code is 2836.